Detalles de la búsqueda
1.
Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.
Cancer Immunol Immunother
; 61(6): 839-54, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22083345
2.
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
Clin Immunol
; 133(3): 333-52, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19762283
3.
Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.
Clin Immunol
; 128(2): 205-18, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18511346
4.
Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
Immunol Invest
; 37(4): 315-38, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18569073
5.
Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
Cancer Res
; 64(1): 406-14, 2004 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14729652
6.
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.
Front Oncol
; 3: 63, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23533029
7.
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.
J Immunother
; 35(2): 196-204, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22306908
8.
CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
J Immunol
; 177(11): 8191-201, 2006 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17114496
9.
Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer.
Clin Immunol
; 111(1): 69-81, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15093554
10.
Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
J Immunol
; 172(3): 1380-90, 2004 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14734713
Resultados
1 -
10
de 10
1
Próxima >
>>